Lay Line Genomics S.p.A. (LLG) is a biopharmaceutical company focused on the discovery and development of innovative therapies for Alzheimer's and other neurological diseases.
Founded in 2001 as a spin out of the International School of Advanced Studies (SISSA) in Trieste , LLG has developed an innovative pipeline of small molecules and biopharmaceuticals to take into clinical development for Alzheimer's and other neurodegenerative diseases. LLG's approach to Alzheimer's disease pursues therapeutic and diagnostic developments in parallel. Lay Line Genomics (LLG) is a private biotechnology company focused on the discovery and development of new drugs and innovative therapies for Alzheimer's and other neurological diseases.
R&D
To view this information, you must subscribe to PL Intelligence.
Partnerships
To view this information, you must subscribe to PL Intelligence.
Deals
To view this information, you must subscribe to PL Intelligence.
Senior management
To view this information, you must subscribe to PL Intelligence.
Contact details
To view this information, you must subscribe to PL Intelligence.
Head office
Lay Line Genomics
Via di Castel Romano 100
Roma
00128 Italy
All rights reserved. Terms and Conditions | Contact us
